Pfizer and BioNTech secured a victory in their legal dispute with Moderna over COVID-19 vaccine patents. On March 5, 2025, the U.S. Patent Trial and Appeal Board ruled that two Moderna patents, which Pfizer and BioNTech were accused of infringing, were invalid. The tribunal concluded that existing knowledge, or “prior art,” invalidated Moderna’s claims.

While this marks a significant win for Pfizer and BioNTech, Moderna has expressed its disagreement with the ruling and is exploring options for an appeal.